ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11,952 GBX | -0.62% |
|
+9.39% | +12.96% |
| 03:11pm | ASTRAZENECA : UBS keeps a Sell rating | ZD |
| 02:11pm | ASTRAZENECA : Deutsche Bank remains Neutral | ZD |
Financials (USD)
| Sales 2024 * | 51.04B | Sales 2025 * | 54.6B | Capitalization | 233B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.61B | Net income 2025 * | 10.23B | EV / Sales 2024 * | 4.95 x |
| Net Debt 2024 * | 19.78B | Net Debt 2025 * | 13.39B | EV / Sales 2025 * | 4.51 x |
| P/E ratio 2024 * |
27.4
x | P/E ratio 2025 * |
23
x | Employees | 89,900 |
| Yield 2024 * |
2.08% | Yield 2025 * |
2.16% | Free-Float | 96.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More press releases
More news
| 1 day | -0.63% | ||
| 1 week | +9.39% | ||
| Current month | +12.14% | ||
| 1 month | +14.69% | ||
| 3 months | +13.54% | ||
| 6 months | +15.22% | ||
| Current year | +12.96% |
1 week
11 004.00
12 144.00
1 month
10 417.6112 144.00
Current year
9 461.0012 144.00
1 year
9 461.0012 186.00
3 years
7 392.0012 392.00
5 years
5 626.0012 392.00
10 years
3 680.0012 392.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 63 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 192 M€ | +13.02% | ||
| 5.17% | 18 M€ | +3.79% | - | |
| 4.89% | 776 M€ | +8.87% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 11,972 | -0.45% | 487 191 |
| 24-04-25 | 12,026 | +5.94% | 4,952,967 |
| 24-04-24 | 11,352 | +0.75% | 3,596,131 |
| 24-04-23 | 11,268 | +0.16% | 3,561,073 |
| 24-04-22 | 11,250 | +2.78% | 3,448,159 |
Delayed Quote London S.E., April 26, 2024 at 09:00 am EDT
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-04-28
- Roadshow - Day 1
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
150.3
USD
Average target price
162.1
USD
Spread / Average Target
+7.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.96% | 233B | |
| +24.35% | 653B | |
| +25.51% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +5.21% | 201B | |
| -10.02% | 193B | |
| -6.47% | 144B | |
| -12.26% | 143B |
- Stock Market
- Equities
- AZN Stock
